39115-11-2

Basic information

• Product Name: 9,10-ANTHRACENEDIONE, 1-(beta-D-GLUCOPYRANOSYLOXY)-4-HYDROXY-
• Synonyms: 9,10-ANTHRACENEDIONE, 1-(beta-D-GLUCOPYRANOSYLOXY)-4-HYDROXY-;1-(β-D-Glucopyranosyloxy)-4-hydroxy-9,10-anthracenedione;4-Hydroxy-9,10-dioxo-9,10-dihydroanthracene-1-yl β-D-glucopyranoside;Quinizarin monoglucoside
• CAS NO: 39115-11-2
• Molecular Formula: C20H18 O9
• Molecular Weight: 0
• Mol File: 39115-11-2.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 9,10-ANTHRACENEDIONE, 1-(beta-D-GLUCOPYRANOSYLOXY)-4-HYDROXY-(CAS DataBase Reference)
• NIST Chemistry Reference: 9,10-ANTHRACENEDIONE, 1-(beta-D-GLUCOPYRANOSYLOXY)-4-HYDROXY-(39115-11-2)
• EPA Substance Registry System: 9,10-ANTHRACENEDIONE, 1-(beta-D-GLUCOPYRANOSYLOXY)-4-HYDROXY-(39115-11-2)

Safety Data

• Hazardous Substances Data: 39115-11-2(Hazardous Substances Data)

Upstream product

• 69657-90-5 1-hydroxy-4-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-9,10-anthracenedione 

Relevant articles and documents

Synthesis of glycoside derivatives of hydroxyanthraquinone with ability to dissolve and inhibit formation of crystals of calcium oxalate. Potential compounds in kidney stone therapy

Synthesis of glycosyl derivatives of hydroxyanthraquinones (6-10) potentially useful for kidney stone therapy is presented. These compounds were analyzed as inhibitors of calcium oxalate crystals formation as well as substances with the ability of dissolving crystalline calcium oxalate. In addition, the effect of the compounds obtained on real kidney stones was analyzed by ex vivo tests. The tests on L929 and A545 cell lines have shown that the compounds obtained were not cytotoxic.